D.J.A. Lobbezoo

731 total citations
14 papers, 490 citations indexed

About

D.J.A. Lobbezoo is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, D.J.A. Lobbezoo has authored 14 papers receiving a total of 490 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Oncology, 10 papers in Cancer Research and 4 papers in Pulmonary and Respiratory Medicine. Recurrent topics in D.J.A. Lobbezoo's work include Breast Cancer Treatment Studies (10 papers), HER2/EGFR in Cancer Research (8 papers) and Cancer Treatment and Pharmacology (7 papers). D.J.A. Lobbezoo is often cited by papers focused on Breast Cancer Treatment Studies (10 papers), HER2/EGFR in Cancer Research (8 papers) and Cancer Treatment and Pharmacology (7 papers). D.J.A. Lobbezoo collaborates with scholars based in Netherlands, United States and Curacao. D.J.A. Lobbezoo's co-authors include Adri C. Voogd, Agnès J. van de Wouw, Roel J.W. van Kampen, Maaike de Boer, Vivianne C. G. Tjan‐Heijnen, Natascha A. J. B. Peters, Frank Peters, J.M.G.H. van Riel, Tineke J. Smilde and M. Wouter Dercksen and has published in prestigious journals such as British Journal of Cancer, Annals of Oncology and European Journal of Cancer.

In The Last Decade

D.J.A. Lobbezoo

14 papers receiving 486 citations

Peers

D.J.A. Lobbezoo

ONCOL

PRM

RNMI

Natascha A. J. B. Peters Netherlands

Anne Favret United States

Carmen Calfa United States

Maggie Wilcox United Kingdom

Fatemeh Lorenz-Salehi Germany

C.H. Barrios Brazil

M. Corona Gainford Canada

Khémaies Slimane France

Ekaterina Trishkina Russia

Ulla Wilking Sweden

Natascha A. J. B. Peters Netherlands

D.J.A. Lobbezoo

392 ×1.0

ONCOL

310 ×1.2

PRM

263 ×1.0

49 ×0.9

RNMI

64 ×1.6

Citations per year, relative to D.J.A. Lobbezoo D.J.A. Lobbezoo (= 1×) peers Natascha A. J. B. Peters

Countries citing papers authored by D.J.A. Lobbezoo

Since Specialization

Citations

This map shows the geographic impact of D.J.A. Lobbezoo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by D.J.A. Lobbezoo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites D.J.A. Lobbezoo more than expected).

Fields of papers citing papers by D.J.A. Lobbezoo

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by D.J.A. Lobbezoo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by D.J.A. Lobbezoo. The network helps show where D.J.A. Lobbezoo may publish in the future.

Co-authorship network of co-authors of D.J.A. Lobbezoo

This figure shows the co-authorship network connecting the top 25 collaborators of D.J.A. Lobbezoo. A scholar is included among the top collaborators of D.J.A. Lobbezoo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with D.J.A. Lobbezoo. D.J.A. Lobbezoo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

14 of 14 papers shown

Mul, Marleen de, Marjolein van der Klift, Annemiek Broijl, et al.. (2023). Improving Outcome-Driven Care in Multiple Myeloma Using Patient-Reported Outcomes: A Qualitative Evaluation Study. Patient. 16(3). 255–264. 3 indexed citations

Lobbezoo, D.J.A., Ingeborg J. H. Vriens, Loes Kooreman, et al.. (2022). The initial hormone receptor/HER2 subtype is the main determinator of subtype discordance in advanced breast cancer: a study of the SONABRE registry. Breast Cancer Research and Treatment. 192(2). 331–342. 1 indexed citations

Ramaekers, Bram, D.J.A. Lobbezoo, Roel J.W. van Kampen, et al.. (2020). Quality of life in a real-world cohort of advanced breast cancer patients: a study of the SONABRE Registry. Quality of Life Research. 29(12). 3363–3374. 14 indexed citations

Geurts, Sandra M. E., Sander Croes, Birgit E. P. J. Vriens, et al.. (2019). A real-life study on the implementation and effectiveness of exemestane plus everolimus per hospital type in patients with advanced breast cancer. A study of the Southeast Netherlands Advanced Breast Cancer registry.. The Breast. 44. 46–51. 1 indexed citations

Kampen, Roel J.W. van, Bram Ramaekers, D.J.A. Lobbezoo, et al.. (2017). Real-world and trial-based cost-effectiveness analysis of bevacizumab in HER2-negative metastatic breast cancer patients: a study of the Southeast Netherlands Breast Cancer Consortium. European Journal of Cancer. 79. 238–246. 12 indexed citations

Kampen, Roel J.W. van, D.J.A. Lobbezoo, Maaike de Boer, et al.. (2017). A real-world study on implementation of bevacizumab in a cohort of HER2-negative metastatic breast cancer patients: A study of the Southeast Netherlands Breast Cancer Consortium. Cancer Treatment and Research Communications. 13. 3–8. 1 indexed citations

Lobbezoo, D.J.A., Wilfred Truin, Adri C. Voogd, et al.. (2016). The role of histological subtype in hormone receptor positive metastatic breast cancer: similar survival but different therapeutic approaches. Oncotarget. 7(20). 29412–29419. 9 indexed citations

Truin, Wilfred, Rudi M. H. Roumen, Sabine Siesling, et al.. (2016). Sentinel Lymph Node Biopsy and Isolated Tumor Cells in Invasive Lobular Versus Ductal Breast Cancer. Clinical Breast Cancer. 16(4). e75–e82. 9 indexed citations

Lobbezoo, D.J.A., Roel J.W. van Kampen, Adri C. Voogd, et al.. (2015). Prognosis of metastatic breast cancer: are there differences between patients with de novo and recurrent metastatic breast cancer?. British Journal of Cancer. 112(9). 1445–1451. 169 indexed citations

10.

Lobbezoo, D.J.A., Roel J.W. van Kampen, Adri C. Voogd, et al.. (2015). In real life, one-quarter of patients with hormone receptor-positive metastatic breast cancer receive chemotherapy as initial palliative therapy: a study of the Southeast Netherlands Breast Cancer Consortium. Annals of Oncology. 27(2). 256–262. 47 indexed citations

11.

Lobbezoo, D.J.A., Maaike de Boer, M. Wouter Dercksen, et al.. (2015). Real-Life Use and Effectiveness of Adjuvant Trastuzumab in Early Breast Cancer Patients: A Study of the Southeast Netherlands Breast Cancer Consortium. The Oncologist. 20(8). 856–863. 30 indexed citations

12.

Boer, Maaike de, et al.. (2014). [Combination of exemestane and everolimus may produce toxic side effects: a new treatment option for metastatic hormone-sensitive breast cancer].. PubMed. 158. A7523–A7523. 1 indexed citations

13.

Lobbezoo, D.J.A., Roel J.W. van Kampen, Adri C. Voogd, et al.. (2013). Prognosis of metastatic breast cancer subtypes: the hormone receptor/HER2-positive subtype is associated with the most favorable outcome. Breast Cancer Research and Treatment. 141(3). 507–514. 186 indexed citations

14.

Vriens, Birgit E. P. J., et al.. (2012). If there is no overall survival benefit in metastatic breast cancer: Does it imply lack of efficacy? Taxanes as an example. Cancer Treatment Reviews. 39(2). 189–198. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact